EER | ENST | ENSG | GeneName | Region | Repeat | dsRNA structure | chr13:40848183-40848776:- | ENST00000379515.3 | ENSG00000168852.11 | TPTE2P5 | ncRNA_intronic | (AC)n,AluSz6,AluJb,L1MEg | chr13:40848183-40848776:-.alignment |
chr13:40848183-40848776:- | ENST00000432905.4 | ENSG00000168852.11 | TPTE2P5 | ncRNA_intronic | (AC)n,AluSz6,AluJb,L1MEg | chr13:40848183-40848776:-.alignment |
chr13:40848183-40848776:- | ENST00000458118.4 | ENSG00000168852.11 | TPTE2P5 | ncRNA_intronic | (AC)n,AluSz6,AluJb,L1MEg | chr13:40848183-40848776:-.alignment |
chr13:40857832-40858006:- | ENST00000379515.3 | ENSG00000168852.11 | TPTE2P5 | ncRNA_intronic | AluSq2,AluY | chr13:40857832-40858006:-.alignment |
chr13:40857832-40858006:- | ENST00000458118.4 | ENSG00000168852.11 | TPTE2P5 | ncRNA_intronic | AluSq2,AluY | chr13:40857832-40858006:-.alignment |
chr13:40881505-40881716:- | ENST00000379515.3 | ENSG00000168852.11 | TPTE2P5 | ncRNA_intronic | MSTB,AluSz | chr13:40881505-40881716:-.alignment |
chr13:40893029-40896142:- | ENST00000379515.3 | ENSG00000168852.11 | TPTE2P5 | ncRNA_intronic | L2a,(AC)n,L1PA5,AluSx,AluJr,FRAM,AluSp,AluSc8 | chr13:40893029-40896142:-.alignment |
chr13:40905482-40907818:- | ENST00000379515.3 | ENSG00000168852.11 | TPTE2P5 | ncRNA_intronic | AluSx,AluJo,AluSx3,MIR3,AluSx1 | chr13:40905482-40907818:-.alignment |
chr13:40919490-40920182:- | ENST00000379515.3 | ENSG00000168852.11 | TPTE2P5 | ncRNA_intronic | AluSz,L1ME3,(TAA)n,AluSx | chr13:40919490-40920182:-.alignment |
ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
chr13:40919490-40920182:- | BRCA | EER | Dendritic_cells_activated | 2.9208e-02 | -0.2119 |  |
ENSG00000168852.11,TPTE2P5 | COAD | EAG | T_cells_follicular_helper | 2.6862e-02 | 0.3544 |  |
chr13:40919490-40920182:- | GBM | EER | Macrophages_M0 | 2.0762e-03 | -0.3962 |  |
ENSG00000168852.11,TPTE2P5 | GBM | EAG | Macrophages_M0 | 2.0762e-03 | -0.3962 |  |
chr13:40919490-40920182:- | LGG | EER | T_cells_regulatory_(Tregs) | 3.8451e-02 | -0.1137 | .chr13_40919490-40920182_-.png) |
ENSG00000168852.11,TPTE2P5 | LGG | EAG | Eosinophils | 3.3359e-02 | 0.1168 |  |
chr13:40919490-40920182:- | LUAD | EER | Macrophages_M1 | 1.3269e-03 | 0.5507 |  |
ENSG00000168852.11,TPTE2P5 | LUAD | EAG | Neutrophils | 4.8718e-04 | 0.4938 |  |
chr13:40919490-40920182:- | OV | EER | Dendritic_cells_resting | 2.5653e-04 | 0.3347 |  |
ENSG00000168852.11,TPTE2P5 | OV | EAG | Dendritic_cells_resting | 1.0226e-04 | 0.3458 |  |
ENSG00000168852.11,TPTE2P5 | PAAD | EAG | B_cells_memory | 1.3489e-02 | 0.4970 |  |
chr13:40919490-40920182:- | PCPG | EER | T_cells_regulatory_(Tregs) | 2.9791e-02 | 0.3576 | .chr13_40919490-40920182_-.png) |
chr13:40919490-40920182:- | SKCM | EER | Mast_cells_activated | 2.5680e-02 | 0.3288 |  |
ENSG00000168852.11,TPTE2P5 | SKCM | EAG | Mast_cells_activated | 2.2407e-02 | 0.3290 |  |
chr13:40881505-40881716:- | STAD | EER | T_cells_gamma_delta | 2.5331e-02 | 0.3624 |  |
chr13:40919490-40920182:- | STAD | EER | Neutrophils | 5.9711e-03 | 0.2846 |  |
chr13:40919490-40920182:- | THCA | EER | T_cells_gamma_delta | 2.5703e-02 | 0.1168 |  |
ENSG00000168852.11,TPTE2P5 | THCA | EAG | T_cells_gamma_delta | 2.5705e-02 | 0.1150 |  |
ENSG00000168852.11,TPTE2P5 | THYM | EAG | Macrophages_M0 | 3.6119e-02 | 0.3324 |  |
chr13:40919490-40920182:- | UCEC | EER | Mast_cells_activated | 1.5437e-02 | -0.3514 |  |
ENSG00000168852.11,TPTE2P5 | UCEC | EAG | Dendritic_cells_activated | 4.1692e-03 | -0.3739 |  |
chr13:40919490-40920182:- | UCS | EER | Dendritic_cells_activated | 4.4603e-02 | 0.4424 |  |
ENSG00000168852.11,TPTE2P5 | UCS | EAG | Dendritic_cells_activated | 4.0010e-02 | 0.4513 |  |
ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
chr13:40919490-40920182:- | BRCA | GSVA_HALLMARK_COAGULATION | EER | 3.1086e-04 | 0.3436 |  |
ENSG00000168852.11,TPTE2P5 | BRCA | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EAG | 1.4798e-04 | 0.3232 |  |
ENSG00000168852.11,TPTE2P5 | COAD | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 1.6329e-02 | -0.3822 |  |
chr13:40919490-40920182:- | GBM | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EER | 4.9809e-03 | 0.3639 |  |
ENSG00000168852.11,TPTE2P5 | GBM | GSVA_HALLMARK_ALLOGRAFT_REJECTION | EAG | 4.9809e-03 | 0.3639 |  |
ENSG00000168852.11,TPTE2P5 | LAML | GSVA_HALLMARK_GLYCOLYSIS | EAG | 3.2829e-03 | 0.3084 |  |
chr13:40919490-40920182:- | LGG | GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE | EER | 1.4711e-03 | 0.1739 |  |
ENSG00000168852.11,TPTE2P5 | LGG | GSVA_HALLMARK_INFLAMMATORY_RESPONSE | EAG | 1.5438e-03 | 0.1731 |  |
chr13:40919490-40920182:- | LUAD | GSVA_HALLMARK_PANCREAS_BETA_CELLS | EER | 4.0424e-02 | 0.3701 |  |
ENSG00000168852.11,TPTE2P5 | PCPG | GSVA_HALLMARK_APICAL_SURFACE | EAG | 4.0958e-02 | -0.3288 |  |
chr13:40919490-40920182:- | PCPG | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 4.7587e-02 | 0.3279 |  |
chr13:40919490-40920182:- | PRAD | GSVA_HALLMARK_PEROXISOME | EER | 2.7934e-02 | 0.1676 |  |
ENSG00000168852.11,TPTE2P5 | PRAD | GSVA_HALLMARK_PEROXISOME | EAG | 3.7790e-02 | 0.1563 |  |
ENSG00000168852.11,TPTE2P5 | SKCM | GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | EAG | 3.9812e-03 | -0.4081 |  |
chr13:40919490-40920182:- | SKCM | GSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | EER | 1.6748e-03 | -0.4506 |  |
chr13:40893029-40896142:- | STAD | GSVA_HALLMARK_GLYCOLYSIS | EER | 3.0279e-02 | 0.2872 |  |
chr13:40919490-40920182:- | STAD | GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING | EER | 1.4304e-02 | 0.2546 |  |
chr13:40905482-40907818:- | STAD | GSVA_HALLMARK_TGF_BETA_SIGNALING | EER | 3.3817e-04 | 0.6592 |  |
ENSG00000168852.11,TPTE2P5 | STAD | GSVA_HALLMARK_MYOGENESIS | EAG | 8.1569e-03 | 0.2111 |  |
ENSG00000168852.11,TPTE2P5 | THCA | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EAG | 1.6252e-03 | 0.1620 |  |
chr13:40919490-40920182:- | THCA | GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY | EER | 3.6600e-04 | 0.1855 |  |
ENSG00000168852.11,TPTE2P5 | THYM | GSVA_HALLMARK_PROTEIN_SECRETION | EAG | 8.1770e-03 | -0.4124 |  |
chr13:40919490-40920182:- | UCEC | GSVA_HALLMARK_FATTY_ACID_METABOLISM | EER | 5.9120e-03 | 0.3956 |  |
chr13:40919490-40920182:- | UCS | GSVA_HALLMARK_GLYCOLYSIS | EER | 1.8289e-02 | 0.5096 |  |
ENSG00000168852.11,TPTE2P5 | UCS | GSVA_HALLMARK_GLYCOLYSIS | EAG | 1.7386e-02 | 0.5130 |  |
ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
chr13:40919490-40920182:- | BRCA | ABT.888 | EER | 2.0034e-04 | 0.3536 |  |
ENSG00000168852.11,TPTE2P5 | BRCA | ABT.888 | EAG | 3.6634e-05 | 0.3498 |  |
ENSG00000168852.11,TPTE2P5 | COAD | Bryostatin.1 | EAG | 1.9098e-02 | -0.3737 |  |
ENSG00000168852.11,TPTE2P5 | ESCA | EHT.1864 | EAG | 1.8801e-02 | -0.3312 |  |
chr13:40919490-40920182:- | GBM | BIBW2992 | EER | 2.7971e-02 | -0.2887 |  |
ENSG00000168852.11,TPTE2P5 | GBM | BIBW2992 | EAG | 2.7971e-02 | -0.2887 |  |
ENSG00000168852.11,TPTE2P5 | LAML | AZD6244 | EAG | 8.2552e-04 | -0.3482 |  |
chr13:40919490-40920182:- | LGG | Lapatinib | EER | 3.1128e-04 | -0.1967 |  |
ENSG00000168852.11,TPTE2P5 | LGG | Lapatinib | EAG | 3.2948e-04 | -0.1959 |  |
ENSG00000168852.11,TPTE2P5 | LUAD | Gemcitabine | EAG | 8.2381e-03 | -0.3850 |  |
chr13:40919490-40920182:- | OV | BIRB.0796 | EER | 4.5718e-02 | -0.1867 |  |
ENSG00000168852.11,TPTE2P5 | PAAD | ATRA | EAG | 3.7117e-03 | 0.5801 |  |
ENSG00000168852.11,TPTE2P5 | PCPG | ATRA | EAG | 1.6616e-02 | 0.3813 |  |
chr13:40919490-40920182:- | PCPG | AG.014699 | EER | 3.6611e-02 | 0.3448 |  |
chr13:40919490-40920182:- | PRAD | AMG.706 | EER | 4.4505e-02 | 0.1534 |  |
ENSG00000168852.11,TPTE2P5 | SKCM | BIBW2992 | EAG | 5.5918e-03 | -0.3940 |  |
chr13:40919490-40920182:- | SKCM | BIBW2992 | EER | 5.8349e-03 | -0.4004 |  |
chr13:40893029-40896142:- | STAD | AZ628 | EER | 3.1050e-02 | -0.2860 |  |
chr13:40881505-40881716:- | STAD | BI.D1870 | EER | 4.5831e-02 | -0.3259 |  |
ENSG00000168852.11,TPTE2P5 | STAD | Bexarotene | EAG | 7.2214e-03 | -0.2143 |  |
ENSG00000168852.11,TPTE2P5 | THCA | BMS.536924 | EAG | 1.2981e-03 | -0.1655 |  |
chr13:40919490-40920182:- | THCA | Embelin | EER | 1.1342e-02 | 0.1324 |  |
ENSG00000168852.11,TPTE2P5 | THYM | AZD6244 | EAG | 5.5398e-04 | -0.5218 |  |
ENSG00000168852.11,TPTE2P5 | UCEC | Axitinib | EAG | 1.7191e-02 | 0.3145 |  |
chr13:40919490-40920182:- | UCEC | Elesclomol | EER | 3.9101e-02 | 0.3020 |  |
chr13:40919490-40920182:- | UCS | AUY922 | EER | 6.5766e-03 | -0.5734 |  |
ENSG00000168852.11,TPTE2P5 | UCS | AUY922 | EAG | 7.4823e-03 | -0.5660 |  |